Oncology Clinical Trials Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 15.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Oncology Clinical Trials Market Analysis
The Global Oncology Clinical Trials Market is expected to register a CAGR of 15% during the forecast period.
The increasing number of cancer cases, the rising need for precision medicines, and high research and development (R&D) spending by the pharmaceutical industry in oncology are key factors driving the market's growth. For instance, according to Cancer Facts and Figures 2024, published in January 2024 by the American Cancer Society, an estimated 2.00 million new cancer cases were diagnosed in 2024, up from 1.93 million in 2023, among which prostate cancer cases were estimated to be 288,300, followed by 238,340 cases of lung cancer and 300,590 cases of female breast cancer. The increased prevalence of cancer and growing demand for effective treatment are likely to lead to a rise in drug development activities, thereby boosting market growth over the forecast period.
The increasing research and development spending on cancer is expected to boost the market over the forecast period. For instance, in August 2022, Griffith University took a significant step forward in cancer research by launching two new research centers with a USD 4.6 million grant from the Australian Cancer Research Foundation (ACRF). Such research initiatives and funding for cancer research programs create opportunities for market players to invest in research and bring advanced oncology drug molecules into the market, which is anticipated to boost market growth over the forecast period.
Moreover, an increase in pipeline drugs from key market players for the treatment of various cancers and the launch of clinical trials are expected to contribute to market growth over the forecast period. For instance, in January 2024, the Royal Surrey NHS Foundation Trust in the United Kingdom reported the commencement of a clinical trial analyzing a vaccine aimed at treating early-stage bowel cancer in patients from both the United Kingdom and Australia.
Similarly, in April 2024, BioNTech SE released three-year follow-up data from a Phase 1 trial on its mRNA-based personalized neoantigen-specific immunotherapy, known as iNeST, under the name autogenous cerumen (BNT122, RO7198457). This trial focused on patients who had undergone surgery for pancreatic ductal adenocarcinoma (PDAC). The results revealed that autogenous cevumeran triggered an immune response in 8 out of 16 patients, lasting up to three years, as evidenced by activated T cells. Notably, patients with sustained T cell presence also showed a prolonged median recurrence-free survival, highlighting the potential of this cancer vaccine. Such ongoing clinical research activities are expected to contribute to market growth over the forecast period.
The oncology clinical trials market is poised for growth, driven by rising cancer cases and increased research and development in oncology. However, strict regulations surrounding patient enrollment in clinical trials act as a constraint on market expansion.
Oncology Clinical Trials Market Trends
Lung Cancer Segment Expected to Register Significant Market Growth Over the Forecast Period
Lung cancer is caused by the uncontrolled growth of abnormal cells that multiply in one or both lungs. There are two major types of lung cancer: non-small cell lung cancer and small cell lung cancer. The reasons for lung cancer include smoking, second-hand smoke, exposure to certain toxins, and family history. The rising prevalence of lung cancer is expected to boost segment growth. As per the American Cancer Society 2024, lung cancer (both small and non-small cell) is the second most common cancer in both men and women. In 2024, an estimated 234,580 people are expected to be diagnosed with lung cancer. Hence, all these factors have been driving the growth of the market.
According to ClinicalTrails.gov, as of June 2024, around 12,190 clinical trials were registered in lung cancer across the various phases of development. The positive outcome of these clinical trials is expected to positively impact the market in the future. Thus, the abovementioned factors are expected to drive market growth over the forecast period.
Additionally, the launch of clinical trials for developing a lung cancer drug is expected to propel the market's growth. For instance, in December 2023, Merck and Moderna Inc. launched the pivotal Phase III INTerpath-002 (NCT06077760) clinical trial of the novel individualized neoantigen therapy V940 (mRNA-4157) in combination with Keytruda (pembrolizumab) as an adjuvant treatment for patients with completely resected Stage II, III A, or III B non-small cell lung cancer (NSCLC).
Thus, all the factors above, such as the growing burden of lung cancer, are expected to boost the market over the forecast period.
North America Expected to Register a Significant Market Share and Continue its Dominance Over the Forecast Period
The North American regional segment is expected to lead the market, mainly due to increasing research and development (R&D) investments, rising government support, and the high incidence of cancer in the population. For instance, according to data published in 2023 by Canadian Cancer Statistics, 239,100 Canadians were diagnosed with cancer. Lung and bronchus (lung), breast, prostate, and colorectal cancers account for almost half of all new cancer cases diagnosed. Thus, the growing burden of cancer and rising demand for innovative cancer therapy are expected to increase the number of clinical trials, thereby boosting market growth.
Moreover, with the increase in cancer cases, clinical trials are expected to rise in the coming years. For instance, according to the National Clinical Trials (NCT) Registry in the United States, as of January 2024, there were around 45,061 ongoing clinical trials related to cancer across the various phases of development. Thus, considering the abovementioned factors, North America will likely experience healthy growth over the forecast period.
The positive outcome of these clinical trials is expected to positively impact the market in the future. For instance, in February 2023, Pfizer announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide), demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous.
Thus, all the abovementioned factors, such as the growing burden of cancer and the increasing number of oncology clinical trials, are expected to boost market growth over the forecast period.
Oncology Clinical Trials Industry Overview
The oncology clinical trials market is fragmented. Major pharmaceutical companies have been found to make enormous investments in R&D, especially in emerging nations, to gain opportunities for market growth in major regions. The strategic partnerships between pharmaceutical companies and CROs are expected to have a significant impact on the market's growth. Some major market players include Novartis AG, Merck & Co. Inc., Bristol Myers Squibb Company, F Hoffmann-La Roche Ltd, and Pfizer Inc.
Oncology Clinical Trials Market Leaders
-
Novartis AG
-
Merck & Co Inc.
-
F Hoffmann-La Roche Ltd
-
Pfizer Inc.
-
Bristol Myers Squibb Company
*Disclaimer: Major Players sorted in no particular order
Oncology Clinical Trials Market News
- January 2024: Ipsen presented for Cabometyx (cabozantinib) in combination with immunotherapy across indications at the American Society of Clinical Oncology Genitourinary Symposium (ASCO GU) that took place from January 25-27, 2024, in San Francisco, United States.
- January 2024: Transgene and NEC Corporation announced the signing of a further development collaboration agreement to continue the clinical evaluation of the individualized neoantigen cancer vaccine, TG4050.
Global Oncology Clinical Trials Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer Worldwide
4.2.2 Increasing Role of Precision and Personalized Medicine for Cancer Treatment
4.3 Market Restraints
4.3.1 Stringent Regulations for Patient Enrollment
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Design
5.2.1 Treatment Studies
5.2.2 Observational Studies
5.3 By Cancer Type
5.3.1 Lung Cancer
5.3.2 Breast Cancer
5.3.3 Leukemia
5.3.4 Prostate Cancer
5.3.5 Other Cancer Types
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Johnson & Johnson
6.1.2 Pfizer Inc
6.1.3 F Hoffmann-La Roche Ltd
6.1.4 Novartis AG
6.1.5 Merck & Co. Inc.
6.1.6 GlaxoSmithKline PLC
6.1.7 Sanofi
6.1.8 AbbVie Inc.
6.1.9 AstraZeneca PLC
6.1.10 Bristol Myers Squibb Company
6.1.11 Eli Lilly and Company
6.1.12 Astellas Pharma Inc.
6.1.13 Boehringer Ingelheim GmbH
6.1.14 Takeda Pharmaceutical Company Limited
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Oncology Clinical Trials Industry Segmentation
As per the scope of the report, oncology clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs. Clinical trial data is mandatory for drug approval and for it to be introduced in the market. These trials are performed under different phases, which depend upon various factors.
The oncology clinical trials market is segmented by phase, design, cancer type, and geography. By phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. By design, the market is segmented into treatment studies and observational studies. By cancer type, the market is segmented into lung cancer, breast cancer, leukemia, prostate cancer, and other cancer types. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market forecasts and sizes in value (USD) for the above segments.
| By Phase | |
| Phase I | |
| Phase II | |
| Phase III | |
| Phase IV |
| By Design | |
| Treatment Studies | |
| Observational Studies |
| By Cancer Type | |
| Lung Cancer | |
| Breast Cancer | |
| Leukemia | |
| Prostate Cancer | |
| Other Cancer Types |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Oncology Clinical Trials Market Research Faqs
What is the current Global Oncology Clinical Trials Market size?
The Global Oncology Clinical Trials Market is projected to register a CAGR of 15% during the forecast period (2024-2029)
Who are the key players in Global Oncology Clinical Trials Market?
Novartis AG, Merck & Co Inc., F Hoffmann-La Roche Ltd, Pfizer Inc. and Bristol Myers Squibb Company are the major companies operating in the Global Oncology Clinical Trials Market.
Which is the fastest growing region in Global Oncology Clinical Trials Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Oncology Clinical Trials Market?
In 2024, the North America accounts for the largest market share in Global Oncology Clinical Trials Market.
What years does this Global Oncology Clinical Trials Market cover?
The report covers the Global Oncology Clinical Trials Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Oncology Clinical Trials Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Oncology Clinical Trials Industry Report
The global oncology market is segmented by phase, design, cancer type, and geography, providing a comprehensive industry overview. The market forecast includes detailed industry analysis and market segmentation, highlighting the market leaders in various regions such as North America, Europe, Asia-Pacific, the Middle-East and Africa, and South America. The report example includes valuable market data, industry trends, and market predictions, offering a thorough market review and industry outlook.
The industry research covers the growth rate and market growth, providing insights into the industry size and market value. The market report also includes a report PDF, which contains industry information and industry statistics. The market analysis focuses on market segmentation and market trends, offering a detailed market overview and market forecast.
The report highlights the importance of market research and the role of research companies in providing accurate market data. The industry reports include a market outlook and market review, offering a comprehensive view of the market segmentation and market value. The industry sales and market predictions are also covered, providing a detailed market overview and market growth.
In summary, the global oncology market report provides a thorough industry analysis, covering all aspects of the market, including growth rate, industry size, industry trends, and market segmentation. The report is an essential resource for understanding the market value and market outlook, offering valuable insights into the market leaders and market predictions. The report PDF is available for download, providing a comprehensive view of the market data and industry information.
